Kevin recently joined NextCure as its Chief Medical Officer. NextCure is a biotech company developing first-in-class immunotherapy based biologics for the treatment of cancer. Previously, he served as head of antibody clinical development at Incyte, where he coordinated immunotherapy clinical development strategies for multiple antibody programs. Kevin received his B.S. in Molecular Biophysics and Biochemistry from Yale University and his M.D. from George Washington University.